title: Infliximab therapy for the treatment of refractory ocular inflammatory disease.
abstract: OBJECTIVE
  To report the outcomes of infliximab therapy in the treatment of ocular inflammatory disease refractory to traditional immunomodulatory therapy (IMT).
  
  
  METHODS
  We retrospectively reviewed the medical records of 27 patients. All patients had noninfectious ocular inflammatory disease refractory to traditional IMT and received 5 mg/kg of infliximab at 2-week to 8-week intervals. Main outcome measures were clinical response, reduction in concomitant IMT, and adverse effects. Cumulative incidences of inflammation control and vision change were calculated using life-table methods.
  
  
  RESULTS
  Twenty-one patients experienced sustained improvement in inflammation with their initial course of infliximab therapy. Cumulative incidence of inflammation resolution at 12 months was greater than 90%. Sixteen patients were able to decrease the dose of their concomitant IMT medication or stop all other IMT. Four patients were able to discontinue all other IMT while receiving infliximab therapy. Three patients with scleritis were eventually able to remain inflammation-free while not taking any medication. At 12 months, 56% and 65% of left and right eyes, respectively, showed visual acuity improvement by 2 or more Snellen lines. Only 1 patient developed an adverse event requiring therapy discontinuation.
  
  
  CONCLUSIONS
  We found a high rate of ocular inflammation control with infliximab therapy. The incidence of adverse effects in this study was low.
authors.affiliation: Massachusetts Eye Research and Surgery Institute, Cambridge, MA 02142, USA.
authors.forename: Lucia
authors.initials: L
authors.lastname: Sobrin
authors.forename: Eva C
authors.initials: EC
authors.lastname: Kim
authors.forename: William
authors.initials: W
authors.lastname: Christen
authors.forename: Thekla
authors.initials: T
authors.lastname: Papadaki
authors.forename: Erik
authors.initials: E
authors.lastname: Letko
authors.forename: C Stephen
authors.initials: CS
authors.lastname: Foster
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015994:Incidence; D007249:Inflammation / Q000517:prevention & control; D000069285:Infliximab; D007262:Infusions, Intravenous; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D031300:Retinal Vasculitis / Q000188:drug therapy*; D012189:Retrospective Studies; D015423:Scleritis / Q000188:drug therapy*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab